84
Participants
Start Date
April 18, 2017
Primary Completion Date
September 6, 2017
Study Completion Date
September 6, 2017
"Omalizumab (JSC GENERIUM, the Russian Federation)"
150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
Xolair® (Novartis Pharma AG, Switzerland)
150 mg of omalizumab was subcutaneously injected once in the deltoid muscle area
"Federal State Budgetary Institution State Scientific Center Institute of Immunology by Federal Medical and Biological Agency of the Russian Federation", Moscow
"State budgetary institution of health care of the city of Moscow City outpatients clinic No. 2 of the Department of Health of the city of Moscow", Moscow
AO GENERIUM
INDUSTRY